BIO-RAD LABORATORIES -CL B (BIO.B) Fundamental Analysis & Valuation
NYSE:BIO.B • US0905721082
281.95 USD
+13.06 (+4.86%)
Last: Mar 4, 2026, 08:10 PM
This BIO.B fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B does not seem to be growing, but still is valued expensively.
1. BIO.B Profitability Analysis
1.1 Basic Checks
- BIO.B had positive earnings in the past year.
- In the past year BIO.B had a positive cash flow from operations.
- In multiple years BIO.B reported negative net income over the last 5 years.
- Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
- BIO.B's Return On Assets of -6.97% is in line compared to the rest of the industry. BIO.B outperforms 52.63% of its industry peers.
- BIO.B has a Return On Equity of -10.03%. This is comparable to the rest of the industry: BIO.B outperforms 54.39% of its industry peers.
- BIO.B's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO.B outperforms 63.16% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BIO.B is significantly below the industry average of 11.61%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- With a decent Operating Margin value of 10.27%, BIO.B is doing good in the industry, outperforming 70.18% of the companies in the same industry.
- In the last couple of years the Operating Margin of BIO.B has remained more or less at the same level.
- BIO.B's Gross Margin of 52.42% is fine compared to the rest of the industry. BIO.B outperforms 63.16% of its industry peers.
- BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. BIO.B Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO.B is destroying value.
- The number of shares outstanding for BIO.B has been reduced compared to 1 year ago.
- BIO.B has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for BIO.B has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.26 indicates that BIO.B is not in any danger for bankruptcy at the moment.
- BIO.B has a better Altman-Z score (3.26) than 71.93% of its industry peers.
- The Debt to FCF ratio of BIO.B is 3.57, which is a good value as it means it would take BIO.B, 3.57 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.57, BIO.B is in the better half of the industry, outperforming 77.19% of the companies in the same industry.
- A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
- BIO.B has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO.B outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.26 |
ROIC/WACC0.21
WACC10.53%
2.3 Liquidity
- A Current Ratio of 5.44 indicates that BIO.B has no problem at all paying its short term obligations.
- The Current ratio of BIO.B (5.44) is better than 80.70% of its industry peers.
- A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
- BIO.B has a better Quick ratio (3.94) than 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. BIO.B Growth Analysis
3.1 Past
- The earnings per share for BIO.B have decreased by -3.78% in the last year.
- Measured over the past years, BIO.B shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.19% on average per year.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
3.2 Future
- The Earnings Per Share is expected to decrease by -2.38% on average over the next years.
- BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.60% yearly.
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. BIO.B Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 28.42, the valuation of BIO.B can be described as expensive.
- Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than 64.91% of the companies in the same industry.
- BIO.B's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.29.
- The Price/Forward Earnings ratio is 27.51, which means the current valuation is very expensive for BIO.B.
- 64.91% of the companies in the same industry are more expensive than BIO.B, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (24.57), we can say BIO.B is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.42 | ||
| Fwd PE | 27.51 |
4.2 Price Multiples
- BIO.B's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 75.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.58 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO.B does not grow enough to justify the current Price/Earnings ratio.
- A cheap valuation may be justified as BIO.B's earnings are expected to decrease with -3.38% in the coming years.
PEG (NY)8.53
PEG (5Y)N/A
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
5. BIO.B Dividend Analysis
5.1 Amount
- BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO.B Fundamentals: All Metrics, Ratios and Statistics
NYSE:BIO.B (3/4/2026, 8:10:21 PM)
281.95
+13.06 (+4.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners90.44%
Inst Owner Change-2.11%
Ins Owners8.17%
Ins Owner ChangeN/A
Market Cap7.61B
Revenue(TTM)N/A
Net Income(TTM)-675.90M
Analysts76
Price Target342.51 (21.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-5.79%
PT rev (3m)-5.79%
EPS NQ rev (1m)-0.28%
EPS NQ rev (3m)-4.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-2.52%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.42 | ||
| Fwd PE | 27.51 | ||
| P/S | 2.97 | ||
| P/FCF | 22.58 | ||
| P/OCF | 15.47 | ||
| P/B | 1.13 | ||
| P/tB | 1.32 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.52%
EPS(NY)10.25
Fwd EY3.64%
FCF(TTM)12.48
FCFY4.43%
OCF(TTM)18.22
OCFY6.46%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)8.53
PEG (5Y)N/A
Graham Number236.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.26 |
F-Score5
WACC10.53%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.06%
EBIT Next 3Y12.74%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 8 / 10.